This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in
recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is
to evaluate the efficacy of anlotinib.
Head and Neck Cancers - Salivary Gland
Clinical Study Identifier
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.